Condition: Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma · Sponsor: PeproMene Bio, Inc.
A Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients with Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL)
This description comes directly from the study's public registry record.
Hazel (Ting-Ying) Cheng, PhD · 714-599-8077 · hazel.cheng@pepromenebio.com
DeShaun Noakes, M.S. · 760-533-4023 · DeShaun.Noakes@pepromenebio.com
Always discuss trial participation with your own doctor first.
| City of Hope Medical Center | Duarte, California, United States | Recruiting |
| Stanford University | Stanford, California, United States | Recruiting |
| University of Kansas Hospital | Kansas City, Kansas, United States | Recruiting |
| University of Minnesota | Minneapolis, Minnesota, United States | Recruiting |
| Atrium Health Levine Cancer Institute - Morehead | Charlotte, North Carolina, United States | Recruiting |
| Providence Swedish Cancer Institute | Seattle, Washington, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05370430